Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
| 3.06 | |
| 3.12 | |
| - | |
| 3.12 | |
| 3.039 | |
| 2.26-13.49 | |
| 21 819 K | |
| 6 993 K | |
| 0 | |
| 0.134 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central n...
In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Bes...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
